43 results
8-K
EX-99.1
VTGN
VistaGen Therapeutics Inc
25 Apr 24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
7:18pm
psychomotor or cognitive impairment caused by mental fatigue. PH15’s proposed MOA targets nasal receptors that activate olfactory-amygdala and olfactory
8-K
EX-99.1
VTGN
VistaGen Therapeutics Inc
3 Jan 24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
5:09pm
-KYNA to off-site targets was identified by an extensive receptor screening study. Moreover, in all clinical trials completed to date, AV-101 has been
424B5
VTGN
VistaGen Therapeutics Inc
3 Oct 23
Prospectus supplement for primary offering
4:40pm
and weight gain.
S-7
AV-101 for Neurological Disorders
AV-101 (4-Cl-KYN) is a novel, oral prodrug that targets the NMDAR (N-methyl-D-aspartate … -KYNA to off-site targets was identified by an extensive receptor screening study. Moreover, in all clinical trials completed to date, AV-101 has been
8-K
EX-99.1
121lms sjfu0sn
13 Jul 23
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
4:35pm
8-K
EX-99.1
h6lmjb6 1w
6 Apr 23
Vistagen Receives New European Patent for AV-101
4:31pm
8-K
EX-99
wly udqpb9q2
29 Jun 21
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
4:09pm
424B5
mw8tgtjknjv6s4ak00
14 May 21
Prospectus supplement for primary offering
4:06pm
8-K
EX-99
w4ro75
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
424B5
1ikem
3 Aug 20
Prospectus supplement for primary offering
8:45pm
424B5
j5q0cf1 rtv6
31 Jul 20
Prospectus supplement for primary offering
4:16pm